Clinical intervention effect of Xuefu Zhuyu decoction on chronic heart failure complicated with depression

BACKGROUND The diagnosis and treatment of depression in patients with chronic heart failure(CHF)is challenging,with no ideal treatment at present.AIM To analyze the clinical intervention effect of Xuefu Zhuyu decoction(XFZYD)on CHF complicated with depression.METHODS The study cohort comprised 116 patients with CHF complicated with depression who received treatment from July 2020 to July 2023,of which 55 received Western medicine(control group)and 61 received XFZYD(research group).Data on clinical effectiveness,traditional Chinese medicine(TCM)syndrome score,cardiac function,negative emotions,and serum inflammatory factors,were collected for comparative analyses.RESULTS Compared with the control group,the research group had an evidently higher total effective rate.Furthermore,there were marked reductions in TCM symptom score,left ventricular end-diastolic diameter,left ventricular end-systolic diameter,Self-Rating Depression Scale,Hamilton Depression Scale,high-sensitivity C-reactive protein,monocyte chemoattractant protein-1,and matrix metalloproteinase-9 in the research group after treatment,and these were lower than the corresponding values in the control group.Left ventricular ejection fraction was increased and higher in the research group compared with the control group after treatment.CONCLUSION Our findings conclusively proved that XFZYD was considerably superior to Western medicine for treating CHF complicated with depression because it significantly alleviated patients’symptoms,improved cardiac function,relieved negative emotions,and reduced the levels of serum inflammatory factors.

Analyzing the pharmacological substances and targets of Xuefu Zhuyu decoction in hypertensive vascular endothelial cells

Background:Xuefu Zhuyu decoction(XFZY)could significantly improve the function of hypertensive vascular endothelial cells,but the targets and mechanism are not clear.This study is to analyze the pharmacological substances and targets of Xuefu Zhuyu decoction in hypertensive vascular endothelial cells.Methods:This study used Xuefu Zhuyu decoction to intervene human umbilical vein endothelial cells incubated by hypertensive patients’serum,then detected the function of vascular endothelial cells.The aqueous extract of XFZY was analyzed and validated by liquid chromatography-mass spectrometry technology;Finally,macromolecular docking technology was used to analyze the potential active substances and targets of XFZY in the prevention and treatment of hypertension.Results:Compared with the model group,the XFZY group showed a significant increase in NO expression(P<0.01)and a significant decrease in ET-1 expression(P<0.001);and the expression of BIP,P-JNK,CHOP,and BAX in XFZY group cells was significantly decreased(P<0.001),while the expression of JNK and BCL2 was significantly increased(P<0.001).19 main compounds were identified in XFZY and there were 3 pairs of molecular complexes with high affinity for markers of the endoplasmic reticulum stress,including BIP-Hesperidin complex,BIP-HSYA complex and JNK-Naringin complex.Conclusion:This study analyzed the potential pharmacodynamic substance and targets of Xuefu Zhuyu decoction in improving the function of hypertensive vascular endothelial cells,which could provide a scientific basis for the future molecular mechanism of XFZY in treating hypertension.

Mechanism of the Xuefu Zhuyu decoction in treating diabetes mellitus erectile dysfunction based on the CaSR/Gq-PLC-PKC pathway

Background:To investigate the mechanism of Xuefu Zhuyu decoction in the treatment of diabetes mellitus erectile dysfunction.Methods:Rats with diabetes mellitus erectile dysfunction were developed using streptozocin and randomly assigned into model,low-dose herbal,and high-dose herbal groups.All rats were administered normal saline or the corresponding drugs by oral gavage for 4 weeks.The related indices were detected using enzyme-linked immunosorbent assays,immunohistochemistry,western blotting,and transmission electron microscopy.Results:The levels of lectin-like oxidized low-density protein receptor-1,endothelin-1,NADH oxidase,vascular cell adhesion molecule-1,and intercellular adhesion molecule-1 in the model group were significantly higher than they were in the mock group but lower than they were in the herbal treatment group.The level of nitric oxide was lower in the model group than was in the mock group but higher than the level in the herbal treatment group.The calcium-sensitive receptor,phospho-protein kinase Cδ/protein kinase Cδ,phosphorylated c-Jun amino-terminal kinase/c-Jun amino-terminal kinase,and phospho-P38 mitogen-activated protein kinase/P38 mitogen-activated protein kinase expression levels in the model group were higher than were in the mock group but lower than were in the herbal treatment group.The structures of the Corpus cavernosum penis endothelial cells were significantly improved in the herbal treatment group than they did in the model group.Conclusion:Xuefu Zhuyu decoction can decrease injury to the endothelium,improve vascular endothelial diastolic and contractive function,and inhibit vascular fibrosis in rats with diabetes mellitus erectile dysfunction.This mechanism may be related to the CaSR/Gq-PLC-PKC pathway.

Systematic Review and Meta-analysis on the Efficacy and Safety of Xuefu Zhuyu Oral Liquid(血府逐瘀口服液)in the Treatment of Migraine

Objective:To systematically evaluate the efficacy and safety of Xuefu Zhuyu Oral Liquid(血府逐瘀口服液)in the treatment of migraine.Methods:All randomized controlled trials(RCTs)on the treatment of migraine with Xuefu Zhuyu Oral Liquid were screened out by systematically searching Cochrane Library,Pub Med,Embase,Web of Science,VIP,Wanfang,CNKI and CBM database from database establishment to March 2023.Literature screening was conducted strictly according to inclusion and exclusion criteria,and the quality of the finally included RCTs was evaluated according to the Cochrane Handbook.All data analyses were completed using Rev Man 5.4 software provided by the Cochrane Collaboration.Results:A total of 8 RCTs involving 706 patients were included.Meta-analysis showed that Xuefu Zhuyu Oral Liquid alone(RR=1.22,95%CI[1.11,1.33],P<0.0001)or combined with conventional treatment(RR=1.19,95%CI[1.11,1.28],P<0.0001)was superior to conventional treatment alone in improving the severity of headache attacks and reducing recurrence.Three studies mentioned mild adverse reactions in individual patients during the treatment process,such as transient diarrhea,lethargy,etc.,which were not directly related to Xuefu Zhuyu Oral Liquid.Conclusion:Based on the existing data and meta-analysis results,Xuefu Zhuyu Oral Liquid alone or combined with conventional treatment can improve the total effective rate of migraine treatment,alleviate headache symptoms,reduce recurrence and adverse events.In the future,large-scale and high-quality original studies are needed to further verify the efficacy and safety of Xuefu Zhuyu Oral Liquid in the treatment of migraine,and provide a reference for the clinical medication of migraine.

Xuefu Zhuyu decoction improves neurological dysfunction by increasing synapsin expression after traumatic brain injury

Xuefu Zhuyu decoction has been used for treating traumatic brain injury and improving post-traumatic dysfunction, but its mechanism of action needs further investigation. This study established rat models of traumatic brain injury by controlled cortical impact. Rat models were intragastrically administered 9 and 18 g/kg Xuefu Zhuyu decoction once a day for 14 or 21 days. Changes in neurological function were assessed by modified neurological severity scores and the Morris water maze. Immunohistochemistry, western blot assay, and re- verse-transcription polymerase chain reaction were used to analyze synapsin protein and mRNA expression at the injury site of rats. Our results showed that Xuefu Zhuyu decoction visibly improved neurological function of rats with traumatic brain injury. These changes were accompanied by increased expression of synaptophysin, synapsin I, and postsynaptic density protein-95 protein and mRNA in a dose-de- pendent manner. These findings indicate that Xuefu Zhuyu decoction increases synapsin expression and improves neurological deficits alder traumatic brain injury.

The efficacy of Xuefu Zhuyu prescription for diabetic encephalopathy: A meta-analysis of randomized controlled trials

Objective:To evaluate the safety and effectiveness of Xuefu Zhuyu Decoction in treating diabetic encephalopathy.Methods:Computer search and manual search of Pub Med,Web of Science,The Cochrane Library,CNKI,WF,VIP and CBM from January 2000 to April 2020 on the treatment of diabetic encephalopathy with Xuefu Zhuyu Decoction In randomized controlled clinical trials,select documents that meet the criteria for analysis using Rev Man 5.3 software.Results:A total of 11 articles and 838 patients were included in the study.Metaanalysis showed that Xuefu Zhuyu Decoction was effective(OR=3.71,95%CI[2.42,5.70],P<0.00001),and the patient’s neurological deficit score(MD=-4.52,95%CI[-5.10,-3.94],P<0.00001),fasting blood glucose(MD=-1.05,95%CI[-1.51,-0.59],P<0.00001),2 hours postprandial blood glucose(MD=-1.31,95%CI[-1.94,-0.69],P<0.00001),glycated hemoglobin(MD=-0.94,95%CI[-1.15,-0.72],P<0.00001),TCM symptom score(MD=-2.44,95%CI[-3.82,-1.06],P=0.0005<0.01),vitality score(MD=12.79,95%CI[8.79,16.79],P<0.00001),the improvement effect is obvious Better than conventional Western medicine treatment.Conclusion:Xuefu Zhuyu Decoction can improve the clinical efficiency of patients with diabetic encephalopathy,reduce brain damage,reduce blood sugar and glycated hemoglobin levels,and has good safety.However,the quality of some of the included literatures is low,and the number of clinical cases is small,which may affect the authenticity of the Meta analysis results.Still need to be further verified by clinical randomized controlled trials with high-quality large samples.

The mechanism of Xuefu Zhuyu decoction in treating erectile dysfunction based on Arrowsmith tool

Arrowsmith,a literature retrieval tool,was used to explore the theoretical pharmacological mechanism of action of Xuefu Zhuyu decoction and its single herb against erectile dysfunction.Cytoscape 3.6.1 software was used to analyze the correlation between the components of Xuefu Zhuyu decoction and the identified mechanism of action.Different herbs in Xuefu Zhuyu decoction may play a therapeutic role by regulating iNOS,COX-2,mTOR,Wnt,AMPK,Nrf2,TLR4,CYP2D6,BDNF,MAPK,Akt,STAT3,PI3K,ERK1,P38MAPK,JNK,VEGF,and other targets.The treatment of erectile dysfunction with Xuefu Zhuyu decoction embodied the multicomponent,multitarget,and multipathway.The Arrowsmith tool retrieval and analysis provided a scientific basis for further elucidation of the mechanism of Xuefu Zhuyu decoction against erectile dysfunction.

The Efficacy of Banxia Baizhu Tianma Decoction(半夏白术天麻汤)Combined with Xuefu Zhuyu Decoction(血府逐瘀汤)for Essential Hypertension and the Effects on Endothelial Function:A Systematic Review and Meta-analysis

Objective:Banxia Baizhu Tianma Decoction(半夏白术天麻汤,BBTD)combined with Xuefu Zhuyu Decoction(血府逐瘀汤,XFZYD)is widely used to treat essential hypertension in China,but its efficacy remains largely unexplored.We systemically summarized relevant evidence from randomized controlled trials(RCTs)to assess the therapeutic efficacy of BBTD+XFZYD.Methods:This review retrieved 6 databases like Pubmed,Cochrane Library,Embase,CNKI,et al.RCTs of BBTD+XFZYD plus conventional Western drugs(experimental group)and conventional Western drugs alone(control group)for hypertension was collected from the database establishment to August 5,2020.And the outcomes included clinical total effective rate,systolic blood pressure(SBP),diastolic blood pressure(DBP),nitric oxide(NO)and endothelin-1(ET-1).All studies’risk of bias were assessed by the Cochrane Collaboration tool 5.1.0.The data was statistically analyzed by RevMan5.3 Software.Results:Six studies with 608 participants were identified.About duration of treatment,4 studies were 1 month,2 studies were 2 months.The quality presented a high risk of bias.The experimental group showed that clinical total effective rate of the 1-month and 2-month was higher(P<0.00001),the systolic pressure was significantly lower(P<0.05),the NO increased(P<0.00001),and the ET-1 decreased(P<0.00001)compared with the conventional Western drugs used alone.However,DBP was significantly lower(P<0.05)at 2 months of treatment.Conclusion:BBTD+XFZYD plus conventional Western drugs might reduce blood pressure,improve clinical efficacy,repair endothelial function,but still need high-quality RCTs to better assess the outcomes.

Identification of prototype compounds and their metabolites in rats’ serum from Xuefu Zhuyu Decoction by UPLC-Q-TOF/MS

Objective: As a classic prescription in traditional Chinese medicine, Xuefu Zhuyu Decoction(XFZYD) has been widely used in the clinical treatment of cardiovascular and cerebrovascular diseases. In order to unveil the potentially effective compounds, a rapid ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry(UPLC-Q-TOF/MS) method was established to identify prototype compounds and their metabolites from XFZYD in rats’ serum.Methods: The serum from rats after intragastric administration of XFZYD aqueous extract was analyzed by UPLC-Q-TOF/MS method. The prototype compounds and their metabolites were identified by comparison with the reference standards and tentatively characterized by comprehensively analyzing the retention time, MS data, characteristic MS fragmentation pattern and retrieving literatures.Results: A total of 175 compounds(24 prototype compounds and 151 metabolites) were identified and tentatively characterized. The metabolic pathways of prototype compounds in vivo were also summarized, including glucuronidation, hydrolyzation, sulfation, demethylation, and hydroxylation, and so on.Conclusion: In this study, a UPLC-Q-TOF/MS technique was developed to analyze prototype compounds and their metabolites from XFZYD in serum, which would provide the evidence for further studying the effective compounds of XFZYD.

Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the Symptoms and Signs and Health-related Quality of Life in the Unstable Angina Patients with Blood-stasis Syndrome after Percutaneous Coronary Intervention: A Randomized Controlled Trial

Objective： Compared with Shengmai Capsule （生脉胶囊, SM）, the study was conducted to evaluate the efficacy and safety of Xuefu Zhuyu Capsule （血府逐瘀胶囊, XFZY） on the symptoms and signs and health-related quality of life （HR-QOL） in the unstable angina （UA） patients with blood-stasis syndrome （BSS） after percutaneous coronary intervention （PCI）. Methods： A randomized, double-blinded, doubledummy, and placebo-controlled trial was applied. Ninety patients, diagnosed as UA and BSS after successful PCI, were enrolled and equally randomized into three groups, XFZY group, SM group, and placebo group, and administered with the corresponding medications respectively for four weeks. The clinical symptoms and signs （CSS）, electrocardiography （ECG）, and BSS scores were recorded and compared among groups during and after the treatment. Short-form 36 （SF-36） and Seattle Angina Questionnaire （SAQ） were applied to assess the HR-QOL in each group before and after the treatment. Safety indexes （blood routine and liver and kidney function tests） were also examined at the beginning and after the treatment. Results： Eighty-six patients completed the whole study. After the treatment, the total effective rates of the XFZY group in ameliorating CSS and ECG were 76.7% and 60.0%, respectively, which were obviously higher than those in SM （CSS： 53.3%; ECG： 36.7%） and the placebo （CSS： 43.3%; ECG： 30.0%） groups. After one week＇s treatment, BSS scores slightly decreased in each group, but no significant differences were found among three groups （P0.05）. After four weeks＇ treatment, BSS scores in the XFZY group decreased to a lower level compared with SM （P0.05） and the placebo （P0.01） groups. After the treatment, the efficacy of XFZY group in improving body pain （BP）, general health （GH）, vitality （VT）, society functioning （SF）, role emotional （RE）, angina stability （AS）, angina frequency （AF）, and treatment satisfaction （TS） were better than those in the placebo group （P0.05, P0.01）. Meanwhile, the dimensions of BP, GH, SF, AS, AF, and TS were better improved than those in the SM group （P0.05）. No obvious adverse reaction was found during and after the treatment except one case in the XFZY group reporting of stomach discomfort. Conclusions： Compared with SM Capsule treatment, a short-term treatment with XFZY Capsule exhibits better efficacy on CSS and BSS scores, and HR-QOL in UA patients with BSS after PCI. However, its long-term efficacy and safety still needs further investigation.

A Microarray Analysis of Angiogenesis Modulation Effect of Xuefu Zhuyu Decoction (血府逐瘀汤) on Endothelial Cells

Objective： To study the angiogenesis modulation mechanism of Xuefu Zhuyu Decoction （血府逐瘀汤） on the endothelial cell line ECV304. Methods： ECV304 cells were treated with 2.5% Xuefu Zhuyu Decoction- containing serum （XFZYD-CS） for 24 h, 48 h or 72 h. Thiazolyl blue tetrazolium bromide （MTT）, fluorescence activating cell sorter （FACS）, migration, adhesion and in vitro tube formation assays were conducted to confirm an angiogenesis effect of XFZYD at 3 time points. An analysis of angiogenesis regulator profiles was performed at 3 times with real-time polymerase chain reaction （RT-PCR） superarray. Results： At 48 h, XFZYD-CS induced ECV304 significantly improved cell viability, number in S phase, migration, adhesion and tube formation. At 24 h and 72 h, only cell migration was elevated. Microarray results showed that the expression of 27 angiogenesis-related genes was changed. Conclusion： XFZYD-CS treatment induced angiogenesis on ECV304 cells with significant cellcular changes occurring at 48 h and genetic changes as early as 24 h.

In Vitro Angiogenesis Effect of Xuefu Zhuyu Decoction(血府逐瘀汤)and Vascular Endothelial Growth Factor:A Comparison Study

Objective： To compare the angiogenesis behaviors of vascular endothelial growth factor（VEGF） and Chinese medicine Xuefu Zhuyu Decoction（血府逐瘀汤,XZD） treatments.Methods： Human microvascular endothelial cells（HMEC-1） were treated with various concentrations of either XZD-containing serum（XZD-CS） or VEGF for 24,48,and 72 h,respectively.Cell viability,proliferation,migration,adhesion,and in vitro tube formation assays were used to assess their angiogenic effects.Results： VEGF promoted all cellular phases involved in angiogenesis including cell viability,proliferation,migration,adhesion,and tube formation（P〈0.05 or P〈0.01）.Unlike the continuous promotion effects of VEGF at the above stages,XZD inhibited cell viability and proliferation（P〈0.05 or P〈0.01） and only promoted tube formation in the early phase of angiogenesis（P〈0.01）.Conclusions： These two medications promote different angiogenesis behaviors,which might be an important reason for their distinct therapeutic profile in clinical usage.

The Effect of Xuefu Zhuyu Decoction(血府逐瘀汤) on in vitro Endothelial Progenitor Cell Tube Formation

Objective： To observe the effect of Xuefu Zhuyu Decoction （血府逐瘀汤）-containing serum （XFZYD-CS） on endothelial progenitor cell （EPC） tube formation in vitro. Methods： Mononuclear cells from rat bone marrow were prepared in a Ficoll density gradient centrifuge. EPCs were separated by the differential attachment method, and observed with inverted microscope for the effect of XFZYD-CS on EPC tube formation. Results： After one day, EPCs exposed to the serum containing 5%, 10% and 15% XFZYD-CS formed typical tubes or vessel networks. The tube formation time was two days ahead of the control group and the size of most tubes in the serum groups was smaller than in the control group. Conclusion： XFZYD-CS could induce EPC angiogenesis and hasten tube formation, especially in capillary vessels. The study provides experimental evidence for the plausibility of Xuefu Zhuyu Decoction in the treatment of ischemic diseases.

Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on Angiogenesis in Hindlimb Ischemic Rats

Objective:To investigate the effect and mechanism of Xuefu Zhuyu Capsule(血府逐瘀胶囊,XZC)on pro-angiogenesis in the hindlimb ischemic model rats.Methods:A total of 100 Sprague Dawley rats were randomly divided into a model group,a regular-dose XZC group(0.48 g·kg^-1·d^-1)and a high-dose XZC group(0.96 g·kg^-1·d^-1)using random number table method.The model of hindlimb ischemic rats were made through femoral artery embolization with Bletilla microsphere age nt.XZC were give n on the first day after embolization surgery and lasted 5 days.Finally 72 models were obtained with 12 in each group for each time point.The lower Ischemic limb was amputated on the third day after embolization surgery.Histopathological characters and the number of blood vessels of granulation tissues were observed at 36 and 48 h after amputation,respectively.The main genes were obtained from microarray analysis and were validated using real-time quarttitative polymerase chain reaction.Results:The vascular number of granulation tissues at both 36 and 48 h were characterized by new and fresh vessels.The number of angiogenesis in the high-dose XZC group at 36 and 48 h was greater compared with that in the regular-dose XZC and model groups(P<0.01),and high-dose XZC at 36 h increased more vessels than that at 48 h(P<0.01).Consequently,granulation tissues from the high-dose XZC group at 36 h were chosen for microarray analysis.In all,2,085 differentially expressed genes(DEGs)were detected and 25 DEGs were determined to be directly related to an giogenesis.Four biological process terms were found including an giogenesis,regulati on of an gioge nesis,positive regulati on of an giogenesis,and positive regulation of vascular end othelial growth factor receptor sign aling pathway(P<0.05).Microarray an alysis also showed 49 pathways including 11 pathways related to an giogenesis.Conclusion:XZC promoted angiogenesis moderately and the mechanism invoIved multiple DEGs and multiple pathways.

Xuefu Zhuyu Oral Liquid (血府逐瘀口服液) Prevents Apoptosis of Ischemic Myocardium Cells in Rats by Regulating SIRT1 and Its Pathway-Related Genes

Objective:To observe the changes of ischemic myocardial cells apoptosis in rats following intervention with Xuefu Zhuyu Oral Liquid(血府逐瘀口服液,XFZY),as well as changes of protein expression of silent information regulator 1(SIRT1)and SIRT1 pathway-related genes.Methods:H9c2 rat myocardial cells were divided into 6 groups:control group,oxygen glucose deprivation(OGD)group,SIRT1 siRNA group,OGD+SIRT1 siRNA group,OGD+XFZY group,and OGD+SIRT1 siRNA+XFZY group.Quantitative fluorescent polymerase chain reaction(PCR)and Western blot were used to detect the concentration variations of SIRT1 and its pathway-related genes and corresponding protein expression after XFZY intervention and SIRT1 transfection.Results:Compared with the control group,the mRNA and protein expressions of SIRT1 were decreased obviously,while the mRNA and protein levels of P53,forkhead box protein O1(FoxO1),FoxO3,FoxO4 and nuclear factor kappa B(NF-κB)were increased in the OGD group,SIRT1 siRNA group,and OGD+SIRT1 siRNA group(P<0.01).Compared with the OGD group and OGD+SIRT1 siRNA group,the treatment of XFZY inhibited the decline in SIRT1 mRNA and protein expressions(P<0.01),and down-regulated the mRNA and protein levels of P53,FoxO1,FoxO3,FoxO4 and NF-κB,respectively(P<0.05 or P<0.01).Conclusion:XFZY could prevent myocardial cells apoptosis probably by increasing the mRNA and protein expressions of SIRT1 and inhibiting the mRNA and protein expressions of P53,NF-κB,FoxO1,FoxO3 and FoxO4.

Effect of EphB4/EphrinB2 Reverse Signal on Angiogenesis Induced by Xuefu Zhuyu Capsule(血府逐瘀胶囊) Containing Serum in Human Microvascular Endothelial Cell 1

Objective： To evaluate the effect of Xuefu Zhuyu Capsule（血府逐瘀胶囊）-containing serum（XFZY-CS） on Eph B4/ephrin B2 and its reverse signal in human microvascular endothelial cell-1（HMEC-1）. Methods： XFZY-CS and the blank control serum were collected. HMEC-1 cells were randomly assigned to 6 groups including the concentration 1.25%, 2.5%, and 5% XFZY-CS groups and their blank serum control ones. The angiogenesis effect of XFZY-CS was tested with an in vitro tube formation assay and the best condition of pro-angiogenesis was determined. The effect of XFZY-CS on Eph B4/ephrin B2 and the reverse signal were determined by Western blot and real-time quantitative polymerase chain reaction, respectively; we also confirmed the results through activating and inhibiting the reverse signal by Eph B4/fc and pyrophosphatase/phosphodiesterase2（PP2）. Results： XFZY-CS promoted angiogenesis at the concentration of 2.5% corresponding serum after being cultured for 48 h, while inhibited angiogenesis at the concentration of 5% after culturing for 48 and 72 h. Under the 2.5% serum concentration, XFZY up-regulated the expression of Eph B4-m RNA at 12 h（P〈0.05）, and down-regulates its expression at 24 h（P〈0.01）. Protein expression of Eph B4 was apparently up-regulated at 12 h and down-regulated at 24 h. The phosphorylation of ephrin B2 increased at 9 h（P〈0.05）. In addition, 2.5% XFZY-CS played a similar role as the reverse signaling activator Eph B4/Fc ranging from 0.5 to 5 μg/m L（P〉0.05）. XFZY-CS also reduced the inhibitive effect of PP2 in limited periods. Conclusion： Eph B4/ephrin B2 was the upstream signal in the process of angiogenesis and its reverse signaling was responsible for XFZY＇s effect on promoting angiogenesis.

Effect of Xuefu Zhuyu Pill (血府逐瘀丸) on Platelet Activating Factor Expression in Patients with Unstable Angina Pectoris

Objective: To explore the significance of platelet activation (PA) in patients with unstable angina pectoris (UA) and the effect of Xuefu Zhuyu pi ll (XZP, a Chinese composite recipe) on it, by way of determining platelet membr ane glycoprotein CD62P, CD41/CD45 expressions in whole blood of healthy persons and UA patients.Methods: XZP was given orally to 45 UA patients for 2 weeks. The ir expressions of CD62P and CD41/CD45 in peripheral blood were determined before and after treatment by whole blood flow cytometry with special marked antibody, and compared with those in 10 healthy persons of the same age as a normal cont rol group. Results: Amount of expressions of CD62P and CD41/CD45 (FC%) in UA patients before treatment were 24.22±7.92 and 25.89±8.10 respectively, all hig her than those in the control group ( P <0.01 and P <0.05). After treatment , CD62P lowered to 20.42±8.01, significantly different from that of before tr eatment( P <0.05), and CD41/CD45 also showed a trend of lowering ( P >0.05). Platelet adhesion rate reduced significantly ( P <0.05) at the same time, as compared with that of before treatment.Conclusion: Highly platelet activated state exists in UA patient s. XZP could inhibit platelet membrane glycoprotein CD62P and CD41/CD45 express ions, which might be the molecular mechanism of it in antagonizing PA.

血府逐瘀汤治疗冠心病研究进展

冠心病是临床常见的心血管疾病之一,其发病率和病死率呈上升趋势,严重危害居民健康,加重国家经济负担。血府逐瘀汤有活血化瘀、理气止痛的功效,主治胸中血瘀证。临床上根据其功效常用于治疗血瘀证冠心病,并取得良好疗效。此文旨在对血府逐瘀汤治疗冠心病的临床运用、作用机制及研究进展展开探讨,为深入挖掘血府逐瘀汤临床及实验研究提供新思路。

真武汤联合血府逐瘀方治疗老年冠心病伴慢性心力衰竭患者的疗效观察

目的探讨真武汤联合血府逐瘀方治疗老年冠心病伴慢性心力衰竭(Chronic heart failure,CHF)患者的临床疗效。方法选取2020年5月—2023年6月期间六安市中医院收治的老年冠心病伴CHF患者106例作为研究对象,依据简单随机数字表法分为对照组和研究组,每组各53例。对照组采取常规治疗,研究组在对照组基础上采取真武汤合血府逐瘀方,均治疗4周。观察比较两组患者临床疗效、不良反应发生情况,治疗前后中医证候积分、心功能[左心室射血分数(Left ventricular ejection fraction,LVEF)、心输出量(Cardiac output,CO)、左心室舒张末期内径(Left ventricular end-diastolic diameter,LVEDD)、左心室收缩末期内径(Left ventricular end-systolic diameter,LVESD)]、血流动力学[肺动脉平均压(Mean pulmonary artery pressure,MPAP)、左心房平均压(Mean left atrial pressure,MLAP)、平均二尖瓣跨瓣压差(Mean mitral valve intervalve pressure difference,MMPG)]、心力衰竭标记物[血管内皮生长因子(Vascular endothelial growth factor,VEGF)、可溶性生长刺激表达基因2蛋白(Soluble growth stimulation expressed gene2,sST2)、脑钠肽(Brain natriuretic peptide,BNP)]水平。结果治疗后研究组临床总有效率94.34%(50/53)明显高于对照组81.13%(43/53),差异有统计学意义(P<0.05)。治疗后两组患者肢冷、心悸、气短、喘促及肢体浮肿、胸闷、盗汗、乏力分值均较治疗前降低,差异有统计学意义(P<0.05);且研究组中医证候积分明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者LVEF、CO指标均较治疗前升高,LVEDD、LVESD指标均较治疗前降低,差异有统计学意义(P<0.05);且研究组LVEF、CO指标明显高于对照组,LVEDD、LVESD指标明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者血流动力学MPAP、MLAP、MMPG水平均较治疗前降低,差异有统计学意义(P<0.05);且研究组血流动力学MPAP、MLAP、MMPG水平明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者VEGF指标均较治疗前升高,sST2、BNP指标均较治疗前降低,差异有统计学意义(P<0.05);且研究组VEGF指标明显高于对照组,sST2、BNP指标均明显低于对照组,差异有统计学意义(P<0.05)。治疗期间,研究组不良反应发生率7.55%(4/53)与对照组3.77%(2/53)比较,差异无统计学意义(P>0.05)。结论常规基础上采取真武汤合血府逐瘀方治疗老年冠心病合并CHF可改善患者心功能,调节血流动力学状态及心力衰竭标记物水平,缓解临床症状,提升整体治疗效果,且具有安全性。

血府逐瘀口服液对狼疮性肾炎患者疗效和安全性评估及血清胸腺肽β4的影响

目的探究血府逐瘀口服液(XZOL)对狼疮性肾炎(LN)患者临床疗效和安全性及血清胸腺肽β4的影响。方法纳入2021年10月至2022年10月河北北方学院附属第二医院诊治的患者为研究对象。采用随机数字表法,将LN患者分为对照组[泼尼松(PDN)+环磷酰胺(CTX)]和血府逐瘀组(XZOL联合PDN+CTX),连续治疗6个月。比较两组治疗有效率、系统性红斑狼疮疾病活动指数(SLEDAI)评分、免疫指标[抗双链DNA抗体(dsDNA)、血清免疫球蛋白(Ig)G和血清补体C3水平]、肾功能指标[血肌酐(Scr)、白蛋白(ALB)、红细胞沉降率(ESR)、谷丙转氨酶(ALT)、24 h尿蛋白和C-反应蛋白(CRP)水平]、血清胸腺肽β4水平和不良反应发生率。结果研究共纳入60例LN患者,每组各30例。血府逐瘀组治疗总有效率明显高于对照组(P<0.05)。治疗前,两组SLEDAI评分、血清胸腺肽β4、IgG、C3、抗dsDNA抗体、血清Scr、ALB、ALT、24 h尿蛋白和CRP水平差异无统计学意义(P>0.05)。治疗6个月后,两组患者SLEDAI评分、血清IgG、抗dsDNA抗体、血清Scr、ALT、24 h尿蛋白和CRP水平均较治疗前显著下降(P<0.05);而血清胸腺肽β4水平、血清C3水平和血清ALB水平显著上升(P<0.05)。且血府逐瘀组SSLEDAI评分、血清IgG、抗dsDNA抗体、血清Scr、ALT、24 h尿蛋白和CRP水平低于对照组(P<0.05);血清胸腺肽β4、C3和ALB水平高于对照组(P<0.05)。此外,两组不良反应发生率差异无统计学分析(P>0.05)。结论XZOL治疗LN临床效果显著,未见明显不良反应,值得在临床推广使用。